2020 CSCO BC Conference . . . Professor Li Jin: The way to develop and innovate anti-tumor drugs in China.
-
Last Update: 2020-07-17
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
"2020 CSCO breast cancer annual meeting and 2020 National Breast Cancer Conference" will be held on schedule from July 10 to 11, 2020.in view of the special situation of the current epidemic situation, the meeting was held in Beijing by combining offline and online methods.at the scientific frontier forum this morning, Professor Li Jin from Shanghai Oriental Hospital gave a keynote talk on the innovation road of anti-tumor drugs in China.the details are as follows: the historical mission of China's innovative pharmaceutical industry, more than 100 years ago, human beings began the extraordinary road of anti-tumor. From 1941 to 2011, scientists have developed a variety of anti-tumor drugs, ranging from hormone therapy for prostate cancer, cisplatin, carboplatin, flurouridine to imatinib, but the contribution of Chinese researchers is not much.the high-risk tumors in China include liver cancer, esophageal cancer and gastric cancer, which are different from those in western countries. However, foreign research mainly focuses on the research and development of high-risk tumor species.therefore, China can not wait for multinational pharmaceutical companies to solve the problem of multiple tumors in China, but rely more on domestic drug innovation.we found that most of the clinical studies conducted up to 2018 were carried out in the United States and Europe. However, the high incidence of cancer in China has not been the focus of their research and development. Of course, it is also related to China's economic status. As can be seen from the figure below, there is a huge difference between China's medical expenditure per capita and that of the world.since the 21st century, Chinese national enterprises have been catching up with each other and the investment in drug research and development has been greatly increased. It is hoped that more enterprises will increase investment in new drug development in the future, so as to have the opportunity to change the current situation.of course, since 2018, the Chinese government has also entered a fast track in promoting the development of new drugs. As of December 4, 2019, CDE has completed 1302 reviews.current situation of innovative drug research in China. In 2014, China's first self-developed new anti-cancer drug apatinib mesylate was put on the market for the third line and above treatment of advanced gastric cancer patients in China.China began to enter the process of independent new drug research and development, and then cedabamine, furoquitinib, treprizumab, pyrrolidine, sufentinib, carrizumab, etc. were successively put on the market. In particular, China's zebitinib has been approved by the U.S. FDA.Chinese new anti-tumor drugs have experienced a difficult process from scratch, from imitation to innovation.citabine is the first subtype selective HDAC inhibitor in the world. It is the first original new drug authorized by China for patent use in the United States and other big countries. It was approved for global marketing in 2015.citabine is the first international class I original drug approved for marketing based on the results of phase II clinical trial in China.furoquitinib is a highly selective tumor angiogenesis inhibitor. It was launched in the world in 2018. The efficacy of furquitinib in the third line treatment of colorectal cancer was widely recognized. It was developed by Hutchison Whampoa and Eli Lilly. This cooperation mode is also needed to provide more opportunities for new drug creation in the future.the phase III study of sufentinib reached the end point one year ahead of schedule, which has a unique mechanism of action. In June this year, the interim analysis of sanet-ep, a key phase III study of sufentinib with advanced non pancreatic neuroendocrine tumor as the indication, has been completed.zgdh3 research is a phase II / III study on donafinil versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma led by Professor Qin Shukui. This year, it has achieved positive and excellent results. Donafinil is a kind of multi-target small molecule anti-tumor drug targeting EGFR / VEGFR. After improvement, its bioavailability and pharmacokinetic characteristics have been significantly improved, and the curative effect is excellent Therefore, this improved exploration is also one of the ways to develop new drugs in the future.problems and prospects: according to the clinical data of new drug application in China, the total number of CDE ind registration and application in 2019 reached 915, including 45.5% of anti-tumor drugs and 60% of domestic products, but the proportion of truly innovative drugs was very small.at present, nearly 10 PD-1 / PD-L1 inhibitors have been listed in China. According to the latest data, more than 50 enterprises have been approved to enter the clinical trials, and more enterprises will join them in the future. It is expected that more than 40 enterprises will list their PD-1 / PD-L1 inhibitors in 2025. This is the problem. We should avoid this homogenization competition.What are the causes of this phenomenon? The main problems in the research and development of anti-tumor drugs in China include policy guidance, quality control of clinical trials, R & D level of pharmaceutical enterprises, main researchers and levels, patient recruitment and R & D costs. Among them, the R & D level of pharmaceutical enterprises is the most important issue. It is hoped that through today's breast cancer conference, the information that drug development needs differentiated survival and avoid homogeneous competition can be conveyed.the following targets are worth exploring: FAK inhibitor, CD73, KRAS, double immune combination.FAK is a non receptor tyrosine kinase inhibitor, which mediates the adhesion of cells to extracellular matrix. Its expression is related to tumor prognosis and the degree of disease metastasis, and is associated with E-cadherin signaling pathway that mediates cell-cell adhesion.a study published in cancer discovery in February this year showed that FAK inhibitors showed effective antitumor effect.and some enterprises in China have started relevant research, which is also one of the ways and directions for China to develop new drugs.CD73 is highly expressed in many tumors, which is also related to immunotherapy. In the future, monoclonal antibody CD73 combined with immunotherapy may become a direction.immunotherapy has been a great success. How to further improve the efficacy and benefit the population is the key issue. Combined immunotherapy is the main direction of drug research and development.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.